Get the Stockscreener App
1.69
3.43%
-0.06
After Hours:
1.75
0.06
+3.55%
Prime Medicine Inc stock is traded at $1.69, with a volume of 1.03M.
It is down -3.43% in the last 24 hours and down -13.33% over the past month.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
See More
Previous Close:
$1.75
Open:
$1.73
24h Volume:
1.03M
Relative Volume:
0.75
Market Cap:
$182.31M
Revenue:
-
Net Income/Loss:
$-217.44M
P/E Ratio:
-0.7788
EPS:
-2.17
Net Cash Flow:
$-205.20M
1W Performance:
+36.29%
1M Performance:
-13.33%
6M Performance:
-58.06%
1Y Performance:
-60.70%
1-Day Range:
$1.62
$1.79
1-Week Range:
$1.20
$1.86
52-Week Range:
$1.115
$8.27
Prime Medicine Inc Stock (PRME) Company Profile
Name
Prime Medicine Inc
Sector
Industry
Phone
617-465-0013
Address
60 FIRST ST., CAMBRIDGE
Compare PRME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
1.69 | 182.31M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| May-20-24 | Initiated | H.C. Wainwright | Buy |
| May-16-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-24 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-24 | Initiated | TD Cowen | Buy |
| Apr-03-24 | Initiated | Wedbush | Outperform |
| Jan-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Oct-09-23 | Initiated | BMO Capital Markets | Outperform |
| Jul-31-23 | Initiated | Guggenheim | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Nov-14-22 | Initiated | Goldman | Neutral |
| Nov-14-22 | Initiated | JP Morgan | Overweight |
| Nov-14-22 | Initiated | Jefferies | Buy |
| Nov-14-22 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prime Medicine Inc Stock (PRME) Latest News
Geode Capital Management LLC Raises Stock Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359 - Seeking Alpha
Top investors say Prime Medicine Inc (PRME) ticks everything they need - Sete News
Prime Medicine Inc (PRME) gets rating Initiated from JMP Securities - knoxdaily.com
Breaking down PRME’s current quarter earnings estimates - uspostnews.com
Analysts Set Prime Medicine, Inc. (NYSE:PRME) Price Target at $13.38 - Defense World
11,426 Shares in Prime Medicine, Inc. (NYSE:PRME) Acquired by American Century Companies Inc. - Defense World
Cathie Wood's Ark Invest Offloads Uipath, Prime Medicine, And Repare Therapeutics - Benzinga
Cathie Wood's Ark Invest Offloads UiPath, Prime Medicine, And Repare Therapeutics - Benzinga
There is no way Prime Medicine Inc (PRME) can keep these numbers up - Sete News
Charles Schwab Investment Management Inc. Acquires 20,614 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Recommendation of “Buy” from Analysts - The AM Reporter
Prime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Analysts Set Prime Medicine, Inc. (NYSE:PRME) Target Price at $13.38 - Defense World
Wedbush Estimates Prime Medicine FY2029 Earnings - The AM Reporter
Wedbush Forecasts Prime Medicine FY2029 Earnings - Defense World
Chardan Capital Forecasts Strong Price Appreciation for Prime Medicine (NYSE:PRME) Stock - Defense World
Prime Medicine (NYSE:PRME) Earns “Buy” Rating from HC Wainwright - Defense World
Why Prime Medicine Stock Was Climbing Higher This Week - AOL.com
Prime Medicine price target raised to $16 from $15 at Chardan - TipRanks
Chardan Raises Price Target on Prime Medicine to $16 From $15, Keeps Buy Rating -March 20, 2025 at 06:45 am EDT - MarketScreener
Why Prime Medicine Stock Is Soaring Today - Yahoo
Prime Medicine’s SWOT analysis: gene editing firm’s stock faces pivotal year - Investing.com India
Prime Medicine’s SWOT analysis: gene editing firm’s stock faces pivotal year By Investing.com - Investing.com South Africa
Prime Medicine announces new α1-antitrypsin deficiency program - BioWorld MedTech
Prime Medicine, Inc.: Promising Future in Gene Editing with Innovative AATD Program and Strategic Growth Potential - TipRanks
H.C. Wainwright maintains Buy on Prime Medicine stock, $10 target By Investing.com - Investing.com Canada
Prime Medicine, Inc.: Innovative Prime Editing Platform Targets Unmet Medical Needs with Promising Preclinical Results - TipRanks
Prime Medicine (NYSE:PRME) Given “Outperform” Rating at Wedbush - Defense World
Prime Medicine’s Promising Advancements in Liver-Targeting AATD Program with Prime Editing Technology - TipRanks
Prime Medicine advances AATD gene editing therapy - Investing.com India
Prime Medicine, Inc.: Innovative Prime Editing Technology and Promising Preclinical Results Drive Buy Rating - TipRanks
Prime Medicine Advances AATD Program With Prime Editing For Potential Curative Treatment - Nasdaq
Wedbush Adjusts Prime Medicine Price Target to $13 From $12, Maintains Outperform Rating - Marketscreener.com
Prime sets sights on liver, lung disease as next target for its gene editing tech - BioPharma Dive
Prime Medicine unveils program for treatment of AATD - TipRanks
Prime Medicine Advances AATD Program with Promising Preclinical Results - TipRanks
Prime Medicine Launches Preclinical Program for Liver Treatments -March 18, 2025 at 07:34 am EDT - Marketscreener.com
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewswire
Revolutionary Gene Editing Breakthrough: Prime Medicine's AATD Treatment Shows 95% Protein Restoration - StockTitan
Prime Medicine, Inc.: Strategic Advancements and Promising Financial Outlook Drive Buy Rating - TipRanks
Cathie Wood's Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta - Benzinga
Chardan Capital Forecasts Prime Medicine FY2025 Earnings - Defense World
Prime Medicine’s SWOT analysis: gene editing firm’s stock poised for pivotal year By Investing.com - Investing.com South Africa
Prime Medicine’s SWOT analysis: gene editing firm’s stock poised for pivotal year - Investing.com
Prime Medicine Inc (PRME)’s Market Momentum: Closing Strong at 2.40, Up 4.35 - The Dwinnex
Is Prime Medicine Inc (NASDAQ: PRME) A Great Stock To Invest In? - Stocks Register
Oppenheimer & Co. Inc. Decreases Stake in Prime Medicine, Inc. (NYSE:PRME) - Defense World
HC Wainwright Expects Increased Earnings for Prime Medicine - Defense World
Citizens JMP maintains $10 target on Prime Medicine stock - Investing.com India
Prime Medicine (NYSE:PRME) Given “Buy” Rating at Chardan Capital - Defense World
Prime Medicine Inc Stock (PRME) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):